Objectives: To evaluate the proficiency of Spanish microbiology laboratories with respect to the antimicrobial susceptibility testing (AST) of Acinetobacter spp.
Introduction
The genus Acinetobacter includes more than 30 genomic species. The most important one from a clinical and epidemiological point of view is Acinetobacter baumannii owing to its ability to acquire MDR and to survive and cause nosocomial outbreaks. 1 Genomic species other than A. baumannii, such as Acinetobacter pittii, are increasingly being recognized as nosocomial pathogens. 2 The prevalence of MDR Acinetobacter spp. has increased in recent years, limiting the treatment options for patients infected with these isolates to some broad-spectrum antimicrobials such as carbapenems. Nevertheless, resistance to carbapenems has also increased in recent years. Data from Europe reported by the European Antimicrobial Resistance Surveillance Network (EARS-Net) showed that in 2015 50% of isolates were carbapenem resistant. 3 One of the best options for the treatment of patients infected with carbapenem-resistant Acinetobacter spp. isolates is colistin, but resistance to this antimicrobial is also increasing. 3 Antimicrobial susceptibility testing (AST) of Acinetobacter spp. may be difficult because there are several factors that can affect the antimicrobial susceptibility results. These factors have been related to the antimicrobial (i.e. the stability of carbapenems, the effect of cation concentrations on the activity of colistin and tigecycline, the type and the age of the medium), the microorganism (i.e. type of intrinsic resistance, type of acquired resistance mechanism, heterogeneity of resistance to colistin or carbapenems) or the methodology (i.e. broth microdilution versus agar disc diffusion). [4] [5] [6] [7] [8] [9] The interpretation criteria employed (i.e. CLSI versus EUCAST) are also factors that affect the interpretation of results. 10 Inferring mechanisms of resistance to antimicrobials forms part of the interpretative reading of the antibiogram. In A. baumannii this is very difficult to do because: (i) resistance is frequently multifactorial; and (ii) the mechanisms of resistance to some antimicrobials are still poorly characterized (i.e. penicillin-binding proteins, heteroresistance).
These limitations led us to perform the present study with the aim of identifying the most frequent problems for AST of Acinetobacter spp. in Spanish clinical microbiology laboratories.
Materials and methods
Bacterial isolates, genomic species identification and antimicrobial susceptibility testing Eight MDR isolates of Acinetobacter spp. with different mechanisms of antimicrobial resistance were selected for this study (Table 1) . Seven isolates of A. baumannii were coded as CC-01 and CC-03 to CC-08, and one isolate of A. pitti was coded as CC-02.
Bacterial identification, antimicrobial susceptibility and confirmation of the mechanisms of resistance were verified independently at Spain's two clinical microbiology reference laboratories: Hospital Universitario Virgen Macarena (Seville), and Complejo Hospitalario Universitario de A Coruña (A Coruña). Identification was performed by partial DNA sequencing of the rpoB gene and MALDI-TOF.
18, 19 The antimicrobials tested were piperacillin/ tazobactam, ampicillin/sulbactam, cefepime, ceftazidime, imipenem, meropenem, ciprofloxacin, levofloxacin, tobramycin, gentamicin, amikacin, colistin and minocycline. The antimicrobials were tested in duplicate at each reference centre by disc diffusion and broth microdilution, according to CLSI guidelines. 20 The 2014 CLSI and EUCAST breakpoints were used to interpret clinical categories.
20,21

Study design
Isolates were sent in Amies transport medium to 48 participating hospitals in May 2014. The instructions specified that isolates should be treated as blood culture isolates. Participating laboratories were asked to fill in an electronic form for each isolate, which included: (i) the laboratory system or method used for AST; (ii) the antimicrobial susceptibility results [inhibition zone diameters or MIC values, and clinical categories: susceptible (S), intermediate (I) and resistant (R)]; (iii) the breakpoints used (CLSI or EUCAST); and (iv) inferred mechanism(s) that might be responsible for the observed phenotype of resistance to carbapenems and colistin.
Data analysis
The analysis of results consisted of: (i) descriptive analysis of AST methods, breakpoints applied, clinical category assigned and discrepancies between centres deriving from these items; (ii) analysis of categorical error rates [minor errors (mEs), major errors (MEs) and very major (VMEs)]; and (iii) the ability of participating laboratories to accurately infer possible underlying resistance mechanisms.
Results
Type of AST system
The laboratories used the following AST systems or methods: 59.4% MicroScan WalkAway (Dade MicroScan Inc., West Sacramento, CA, USA), 18.5% Vitek 2 (bioMérieux, Marcy-l'Étoile, France), 11.0% Wider I (Francisco Soria Melguizo, Madrid, Spain), 3.7% disc diffusion, 3.6% Etest, 3.5% Phoenix (BD Biosciences, Sparks, MD, USA) and 0.4% Sensititre (Trek Diagnostic systems, Westlake, OH, USA).
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(Vitek 2 and Sensititre), 10.7% (Wider I), 9.8% (MicroScan WA) and 3.1% (Phoenix). The discrepancies using disc diffusion were 4.1%. Table 2 shows the distribution of categorical error rates according to type of AST system.
Breakpoints applied and type of antimicrobial agent
The participating laboratories registered 4693 (94.5%) results in the database. Some of the antimicrobials most frequently not tested were ampicillin/sulbactam (26.4%), minocycline (25.3%), levofloxacin (19.0%) and piperacillin/tazobactam (15.4%). Sixty-five percent of the 48 participating laboratories exclusively applied CLSI breakpoints, whereas 19% applied only EUCAST breakpoints and 16% applied CLSI or EUCAST breakpoints depending on the antimicrobial. For all antimicrobials tested the overall discrepancy rates in clinical category due exclusively to the differential use of breakpoints were 20.5% by applying CLSI breakpoints, and 10.8% by applying EUCAST breakpoints (Table 3) . By using CLSI breakpoints high percentages of discrepancies were observed for ampicillin/sulbactam (56.2%), minocycline (40.7%), tobramycin (38.7%), imipenem (27.8%) and meropenem (25.4%). In contrast, using EUCAST breakpoints the greatest discrepancies were obtained for imipenem (30.0%), meropenem (20.8%) and tobramycin (16.8%).
There was a high proportion of mE (80.1% using CLSI breakpoints and 58.4% using EUCAST breakpoints), particularly for levofloxacin, cefepime, ampicillin/sulbactam, minocycline, tobramycin and meropenem using CLSI breakpoints, and for levofloxacin, meropenem and imipenem using EUCAST breakpoints (Table 3 ). The percentages of MEs (false resistance) were 3.5% using CLSI breakpoints, and 12.4% using EUCAST breakpoints. The highest ME rates were observed for colistin, gentamicin and amikacin using CLSI breakpoints, and for colistin, tobramycin, gentamicin and amikacin using EUCAST breakpoints. The percentages of VME (false susceptibility) were 16.4% using CLSI breakpoints and 29.2% using EUCAST breakpoints. The highest VME rates were observed for colistin, imipenem, ceftazidime and amikacin using CLSI breakpoints, and for gentamicin, tobramycin, colistin and amikacin using EUCAST breakpoints.
Type of reference isolate
Discrepancies in the MICs by type of reference isolate (Table 4) were .50% and ranged from 51.0% (CC-06) to 56.5% (CC-03), whereas categorical error rates ranged from 7.4% (CC-03) to 16.8% (CC-04) for mE, 0.0% (CC-03) to 4.4% (CC-04) for ME and 1.0% (CC-03) to 5.2% (CC-06) for VME.
The highest percentages of mE and ME were observed with the CC-04 isolate (bla OXA-24 ), whereas the highest percentages of VME were observed with the CC-06 (bla OXA-24 and resistant to colistin by pmrAB mutation) and CC-05 isolates (bla OXA-24 and heteroresistant to carbapenems).
Ability of centres to infer resistance mechanisms
The analysis of inferred mechanisms of resistance focused only on b-lactams, particularly carbapenems, and colistin owing to the heterogeneous information reported by the participating laboratories. Only one centre inferred ESBL production in the bla CTX-M-15 -producing isolate (CC-01). With respect to the bla OXA-58 -producing isolate (CC-02), 11 laboratories indicated carbapenemase production, but only 3 specified that it was a class D carbapenemase. Of the 19 centres that reported the bla IMP -producing isolate (CC-03) as a carbapenemase producer, only 4 specified production of a class B carbapenemase. Only 1 centre reported that the bla OXA-24 -producing isolate (CC-04) was a carbapenemase producer. With respect to the bla OXA-24 -producing isolate heteroresistant to carbapenems (CC-05), 9 centres inferred carbapenemase production but none reported the carbapenem-heteroresistant phenotype. For the bla OXA-24 -producing isolate resistant to colistin (CC-06), 14 centres reported this isolate to be a colistin-resistant pmrAB mutant. Carbapenemase production in the bla OXA-24 -producing isolate overexpressing adeABC (CC-07) was inferred by 14 participating centres, but overexpression of adeABC was not mentioned. Finally, for the bla OXA-51 -hyperproducing isolate deficient in omp33-36 (CC-08), 16 centres reported carbapenemase production, but none inferred porin loss.
Discussion
Most laboratories use either automated and/or manual systems or methods with different performances for AST. Erroneous antimicrobial susceptibility results have been described in Acinetobacter spp. and have been associated with several factors. In our study, the discrepancies observed in antimicrobial susceptibility results provided by participating centres were related to the AST system used, the differential application of CLSI or EUCAST breakpoints, the antimicrobial and the type of isolate.
The type of assay or method used for AST was a possible contributory factor to the discrepancies observed in this study. The Etest was the least reliable method for AST with 18.5% of discrepancies in the MICs. Among automated AST systems, the least reliable ones were Vitek 2 and Sensititre. All the AST methods, except Phoenix, showed too many mEs (75%). The highest percentages of ME and VME were obtained using the Phoenix system, suggesting that this AST system performs poorly. Nevertheless, The highest percentages are shown in bold.
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these results should be interpreted with caution as only two centres used the Phoenix method for AST. VMEs were also elevated, particularly using Etest, but not when using Sensititre or disc diffusion with which no VMEs were detected. In the study by Kulah et al., 7 whose objective was to detect imipenem resistance in A. baumannii using three automated systems (BD Phoenix, MicroScan WalkAway, Vitek 2), it was observed that the highest error rates (25% VME and 44.6% mE) and the worst performance in susceptibility testing occurred with the MicroScan WA system. The study by Akers et al. 22 showed that disc diffusion and Etest tended to be more accurate than the Vitek 2, Phoenix and MicroScan automated systems, with VMEs of 5.6% and 13.1% for tobramycin and amikacin, respectively, using Vitek 2.
Discrepancies in the clinical category derived from the breakpoints or guidelines applied may have no effect on the clinical category or may result in a high categorical error rate. In the present study higher discrepancies using CLSI breakpoints when compared with those of EUCAST breakpoints are mainly due to mE and to a much lesser extent to ME or VME, suggesting that the breakpoint used is an important factor contributing to antimicrobial susceptibility discrepancies and errors in clinical category. With respect to the categorical error rates, the overall percentages of mE using CLSI breakpoints were higher than those obtained using EUCAST breakpoints.
In contrast, the percentages of ME and VME were higher using EUCAST breakpoints. Categorical error rates (mE and VME) for ampicillin/sulbactam and minocycline were associated particularly with the use of CLSI breakpoints. For imipenem and meropenem, elevated mEs were observed independent of the breakpoints used (CLSI or EUCAST), whereas VMEs were much more frequent using CLSI breakpoints. For tobramycin the errors were associated with the use of CLSI breakpoints (mE) and EUCAST breakpoints (ME and VME).
Type of antimicrobial was another factor contributing to the discrepancies and errors observed. The antimicrobials that showed the highest discrepancies in susceptibility associated with high categorical error rates were levofloxacin, ampicillin/sulbactam, imipenem, meropenem, tobramycin and minocycline, which coincides with some previous studies. 7, [21] [22] [23] [24] [25] Susceptibility to b-lactams may be difficult to test in the laboratory for several reasons. When the assay is performed by broth microdilution, subtle growth patterns (i.e. granular, small button or 'starry' growth) are frequently observed, making the results difficult to interpret and leading to elevated MEs. 23 Using disc diffusion The highest percentages are shown in bold. The highest percentages are shown in bold.
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JAC methods, problems of interpretation have also been observed related to the presence of colonies growing inside the inhibition halo. The stability of b-lactams is another factor that could lead to discrepancies in susceptibility. This is particularly relevant for carbapenems, which are very labile, and for which false resistance (VME) is frequently detected, particularly using some automated devices.
The number of laboratories able to infer some type of mechanism of resistance was very low, with .50% reporting discrepancies in clinical categories, reflecting the difficulty of inferring resistance mechanisms in Acinetobacter, particularly with antimicrobials such as carbapenems. As mentioned before, this kind of inference is complicated by the presence of various resistance mechanisms (namely, hyperexpression of the bla OXA-51 carbapenemase and some of the acquired carbapenem-hydrolysing oxacillinases described in A. baumannii) and by the fact that mechanisms of resistance to some antimicrobials in Acinetobacter spp. have not been studied to the extent of Enterobacteriaceae or Pseudomonas aeruginosa. In our study, a high degree of disagreement was found when inferring resistance mechanisms, particularly for most MDR or carbapenem-resistant isolates with acquired mechanisms of carbapenem resistance, for which the percentage of mE and VME was unacceptably high.
An analysis of factors that contribute to antimicrobial susceptibility results should be a priority for clinical laboratories. One way to address this problem is to participate in quality control programmes, which can be very helpful for detecting potential laboratory problems and enabling corrective measures to be established for optimizing the process and the quality of the reports offered to clinicians. This information is very useful for optimizing the best therapeutic strategies, improving the rational use of antimicrobials (reducing resistance rates) and facilitating the control of nosocomial infections (by reducing transmission of MDR clones) so as to avoid outbreaks. [26] [27] [28] [29] In conclusion, this study clearly shows that microbiology laboratories need to improve their ability to accurately determine the antimicrobial susceptibility of Acinetobacter spp. This is particularly relevant for ampicillin/sulbactam, carbapenems and tobramycin, and when both automated devices and CLSI breakpoints are used. The higher discrepancies using CLSI breakpoints are mainly related to mEs and in a much lesser extent to MEs or VMEs.
